Healthcare
Global Pharma Giants Bet Big on Chinese Biotech: 4 Deal-Making Trends for 2026
Cross-border pharma-biotech deals involving Chinese companies surged past $48 billion in the first seven months of 2026. Here are 4 deal trends foreign pharma executives and investors need to track.
How Record 10 Brand-Name Drugs Winning China Bulk-Buying Bids Affects Foreign Pharma: 2026 Update
A record 10 brand-name drugs won bids in China's 10th round of centralized drug procurement on August 5, 2026, as NHSA introduced a dual-pathway selection mechanism. Here's the new market-access math for multinational pharmaceutical companies.
How Global GLP-1 Drug Demand Is Fueling China’s Pharma CDMO Boom: 2026 Update
WuXi AppTec's shares surged 37% in H1 2026 as global GLP-1 weight-loss drug orders flooded China's CDMO sector. With peptide reactor capacity growing twelvefold to 100,000 liters, here's what the pharma manufacturing boom means for your foreign biotech or pharmaceutical business.
How a Foreign Biotech Startup Entered China’s Precision Medicine Market: Case Study
How a Foreign Biotech Startup Entered China's Precision Medicine Market: Case Study In 2023, NovaOnco Therapeutics, a US-based AI biotech startup, exe
How Legend Biotech Secured FDA Approval for CAR-T Therapy: Case Study
How Legend Biotech Secured FDA Approval for CAR-T Therapy: A China Biotech Case Study This case study examines how Legend Biotech (传奇生物, Legend Biotec
How BeiGene Built a Billion-Dollar Biotech in China: Case Study
How BeiGene Built a Billion-Dollar Biotech in China: Case Study How BeiGene Built a Billion-Dollar Biotech in China: Case Study The story of BeiGene's